<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02813200</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2014/22</org_study_id>
    <nct_id>NCT02813200</nct_id>
  </id_info>
  <brief_title>Description of the Ability to Learn How to Handle Inhaler Devices in COPD</brief_title>
  <acronym>INTUITIVE</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death in the
      world and further increase in its prevalence and mortality has been predicted. Currently, the
      main long-term treatments are the long-acting beta-2 agonist, indacaterol, salmeterol and the
      anticholinergic drug, tiotropium and glycopyrronium, used alone or in combination:

        -  long-acting beta-2 agonist with corticosteroid (e.g. salmeterol/fluticasone),

        -  long-acting beta-2 agonist with anticholinergic (e.g. indacatetrol/glycopyrronium).

      These drugs are delivered to the lung using different inhaler devices such as Breezhaler ®,
      Handihaler® and Diskus®.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The correct use of inhaler devices is an inclusion criterion in COPD clinical trials. In real
      life, patients may make many errors using their own inhaler device, which may alter the
      positive effects observed in clinical trials.

      The main objective of this study is to describe the handling of inhaler devices
      (indacaterol-glycopyrronium Breezhaler®, tiotropium Respimat® and salmeterol-fluticasone
      Diskus®) in patients with COPD.

      All participants will receive each of the three treatments (Seretide® Diskus® 500/550 μg,
      Ultibro® Breezhaler® 110/50 μg and Spiriva® Respimat® 2,5 μg). Each treatment will be given
      daily for one week, followed by a 7-day washout period.

      On day 1 of each treatment period, the patient will have clinical examination, lung function
      testing (FEV1) and 2 video recordings:

        -  Video recording #1: inhalation (one puff) without any instruction of use,

        -  Video recording #2: inhalation (one puff) after reading the patient information leaflet.

      At the end of the visit, the patient will watch a standardized video demonstrating correct
      inhaler technique.

      On day 7 of each treatment period, the patient will have clinical examination, lung function
      testing (FEV1) and 1 video recording of inhaler device use (one puff).

      30 days after the last visit, the patient will have a phone contact to collect the adverse
      events.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the presence of at least a major error in the use of the inhalation system, from standardized checklist</measure>
    <time_frame>Day 7 of each treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of non critical errors from standardized checklist</measure>
    <time_frame>Day 7 of each treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of non device-dependant errors from standardized checklist</measure>
    <time_frame>Day 7 of each treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of the time necessary for drug administration</measure>
    <time_frame>Up to day 7 of each treatment</time_frame>
    <description>Time in second</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of Forced Expiratory Volume in 1 second (FEV1)</measure>
    <time_frame>At baseline and at day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collection of adverse events</measure>
    <time_frame>Up to day 66</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seretide® Diskus® 500/550 μg</intervention_name>
    <description>Every day during 7 days</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ultibro® Breezhaler® 110/50 μg</intervention_name>
    <description>Every day during 7 days</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spiriva® Respimat® 2,5 μg</intervention_name>
    <description>Every day during 7 days</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged more than 40 years,

          -  Written informed consent,

          -  Diagnosis of COPD according to international guidelines (GOLD 2012),

          -  Social security or health insurance,

          -  Women of childbearing potential with a very effective contraception according to the
             Haute Autorité de Santé (HAS) recommendations.

        Exclusion Criteria:

          -  Previous treatment with Breezhaler®, Diskus® or Respimat® or similar device,

          -  QT ≥ 450 ms,

          -  Contraindications to tiotropium: hypersensitivity to tiotropium,

          -  Contraindications to indacatérol: hypersensitivity to indacatérol,

          -  Contraindications to salmeterol: hypersensitivity to salmeterol,

          -  Contraindications to fluticasone: hypersensitivity to fluticasone,

          -  Contraindications to glycopyrronium: hypersensitivity to glycopyrronium,

          -  COPD exacerbation within 6 weeks before inclusion,

          -  Chronic psychiatric disease,

          -  Medical condition that may affect handling of inhaler devices,

          -  Subject deprived of his/her liberty,

          -  Protected adult,

          -  Subject in exclusion period related to another protocol,

          -  Pregnant or breastfeeding woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hélène PEYROUZET, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Service Hospitalo-Universitaire de Pharmacologie Médicale</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre-Olivier GIRODET, Dr</last_name>
    <phone>(0)5 57 62 31 94</phone>
    <phone_ext>+33</phone_ext>
    <email>pierre-olivier.girodet@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Virginie NIEL</last_name>
    <phone>(0)5 57 62 31 94</phone>
    <phone_ext>+33</phone_ext>
    <email>virginie.niel@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CIC-P - Centre François Magendie - G3 - Hôpital Haut-Lévêque</name>
      <address>
        <city>Bordeaux</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre-Olivier GIRODET, Dr</last_name>
      <phone>(0)5 57 62 31 94</phone>
      <phone_ext>+33</phone_ext>
      <email>pierre-olivier.girodet@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Virginie NIEL</last_name>
      <phone>(0)5 57 62 31 94</phone>
      <phone_ext>+33</phone_ext>
      <email>virginie.niel@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Pierre-Olivier GIRODET, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick BERGER, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2016</study_first_submitted>
  <study_first_submitted_qc>June 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2016</study_first_posted>
  <last_update_submitted>June 22, 2016</last_update_submitted>
  <last_update_submitted_qc>June 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD, inhaler device, handling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

